{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:30:18Z","timestamp":1787837418113,"version":"build-2784847793"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Research on rare genetic diseases is challenging due to their low prevalence and complex clinical manifestations. Despite their individual rarity, the cumulative burden of these diseases is substantial. Larger claims databases could enable a quantification and characterization of patients with rare diseases and contribute to determining their specific healthcare needs. This study examines the prevalence, comorbidities, and annual direct costs of Huntington\u2019s disease (HD), Beta-Thalassemia (BT), and Spinal Muscular Atrophy type 1 (SMA type 1) in Germany.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Utilizing anonymized claims data from the InGef research database, we conducted a cross-sectional analysis for each disease from 2017 to 2023. Patients and comorbidities were identified based on ICD-10-GM-codes. Prevalence was extrapolated to the German population. Costs were analyzed as direct costs per patient and by sector incurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Prevalences for the selected diseases were 6.65 (HD), 12.81 (BT), and 1.24 (SMA type 1) patients per 100,000 persons in Germany in 2023. The most frequent comorbidities identified are strongly related to the specific disease. For instance, in 2023, among the most common diagnoses were depression in HD patients (38.48%), dorsalgia in BT patients (37.03%), and acute upper respiratory infections in SMA type 1 patients (45.19%). Average total direct costs in 2023 amounted to 9,527.89 \u20ac for HD, 6,656.27 \u20ac for BT and 144,585.02 \u20ac for SMA type 1, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Claims data enable robust identification and characterization of rare disease populations. The findings on prevalences and comorbidities align with existing literature and support the use of such data for treatment planning and post-marketing studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-04147-8","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T02:05:19Z","timestamp":1764295519000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Epidemiology and economic burden of selected rare genetic diseases in Germany \u2013 a claims database study"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2446-0090","authenticated-orcid":false,"given":"Marion","family":"Ludwig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Alibone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raeleesha","family":"Norris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vukasin","family":"Viskovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Cengia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Oberm\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"issue":"12","key":"4147_CR1","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1002\/mds.29228","volume":"37","author":"A Medina","year":"2022","unstructured":"Medina A, Mahjoub Y, Shaver L, Pringsheim T. Prevalence and incidence of huntington\u2019s disease: an updated systematic review and Meta-Analysis. Mov Disord. 2022;37(12):2327\u201335.","journal-title":"Mov Disord"},{"key":"4147_CR2","doi-asserted-by":"crossref","unstructured":"Verhaart IEC, Robertson A, Wilson IJ, Aartsma-Rus A, Cameron S, Jones CC, et al. Prevalence, incidence and carrier frequency of 5q\u2013linked spinal muscular atrophy \u2013 a literature review. Orphanet J Rare Dis. 2017 July 4;12(1):124.","DOI":"10.1186\/s13023-017-0671-8"},{"issue":"1","key":"4147_CR3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12874-019-0713-0","volume":"19","author":"M Pai","year":"2019","unstructured":"Pai M, Yeung CHT, Akl EA, Darzi A, Hillis C, Legault K, et al. Strategies for eliciting and synthesizing evidence for guidelines in rare diseases. BMC Med Res Methodol. 2019;19(1):67.","journal-title":"BMC Med Res Methodol"},{"key":"4147_CR4","unstructured":"BfArM -, Alpha. -ID-SE [Internet]. [cited 2024 Nov 11]. Available from: https:\/\/www.bfarm.de\/DE\/Kodiersysteme\/Terminologien\/Alpha-ID-SE\/_node.html"},{"key":"4147_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.puhe.2022.02.013","volume":"206","author":"M Ludwig","year":"2022","unstructured":"Ludwig M, Enders D, Basedow F, Walker J, Jacob J. Sampling strategy, characteristics and representativeness of the InGef research database. Public Health. 2022;206:57\u201362.","journal-title":"Public Health"},{"key":"4147_CR6","unstructured":"Deutsches Institut f\u00fcr Medizinische Dokumentation und Informatik (DIMDI.), editor. OPS Version 2020 Systematisches Verzeichnis - Operationen- und Prozedurenschl\u00fcsselInternationale Klassifikation der Prozeduren in der Medizin (OPS) Band 1: Systematisches Verzeichnis. 2019."},{"key":"4147_CR7","unstructured":"WIdO \u2013 Wissenschaftliches Institut der AOK [Internet]. [cited 2021 July 7]. Amtliche ATC-Klassifikation. Available from: https:\/\/www.wido.de\/publikationen-produkte\/arzneimittel-klassifikation\/amtliche-atc-klassifikation\/"},{"key":"4147_CR8","unstructured":"Statistisches Bundesamt [Internet]. [cited 2025 Apr 14]. Bev\u00f6lkerung nach Altersgruppen. Available from: https:\/\/www.destatis.de\/DE\/Themen\/Gesellschaft-Umwelt\/Bevoelkerung\/Bevoelkerungsstand\/Tabellen\/bevoelkerung-altersgruppen-deutschland.html."},{"issue":"1","key":"4147_CR9","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1186\/s12883-019-1556-3","volume":"19","author":"C Ohlmeier","year":"2019","unstructured":"Ohlmeier C, Saum KU, Galetzka W, Beier D, Gothe H. Epidemiology and health care utilization of patients suffering from huntington\u2019s disease in germany: real world evidence based on German claims data. BMC Neurol. 2019;19(1):318.","journal-title":"BMC Neurol"},{"issue":"1","key":"4147_CR10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3233\/JND-221577","volume":"10","author":"W M\u00fcller-Felber","year":"2023","unstructured":"M\u00fcller-Felber W, Blaschek A, Schwartz O, Gl\u00e4ser D, Nennstiel U, Brockow I, et al. Newbornscreening SMA \u2013 From pilot project to nationwide screening in Germany. J Neuromuscul Dis. 2023;10(1):55.","journal-title":"J Neuromuscul Dis"},{"issue":"11","key":"4147_CR11","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1007\/s00112-018-0544-9","volume":"166","author":"H Cario","year":"2018","unstructured":"Cario H, Lobitz S. H\u00e4moglobinopathien Als herausforderung der migrantenmedizin. Monatsschr Kinderheilkd. 2018;166(11):968\u201376.","journal-title":"Monatsschr Kinderheilkd"},{"issue":"6","key":"4147_CR12","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/ejh.13512","volume":"105","author":"A Kattamis","year":"2020","unstructured":"Kattamis A, Forni GL, Aydinok Y, Viprakasit V. Changing patterns in the epidemiology of \u03b2-thalassemia. Eur J Haematol. 2020;105(6):692\u2013703.","journal-title":"Eur J Haematol"},{"key":"4147_CR13","unstructured":"Gesellschaft f\u00fcr P\u00e4diatrische Onkologie und H\u00e4matologie. S1-Leitlinie Thalass\u00e4mien [Internet]. 2023 [cited 2024 Mar 19]. Available from: https:\/\/www.awmf.org\/leitlinien\/detail\/ll\/025-017.html"},{"key":"4147_CR14","doi-asserted-by":"crossref","unstructured":"Anil M, Mason SL, Barker RA. The clinical features and progression of Late-Onset versus Younger-Onset in an adult cohort of huntington\u2019s disease patients. J Huntingt Dis. 9(3):275\u201382.","DOI":"10.3233\/JHD-200404"},{"key":"4147_CR15","doi-asserted-by":"crossref","unstructured":"Solberg OK, Filkukov\u00e1 P, Frich JC, Feragen KJB. Age at death and causes of death in patients with huntington disease in Norway in 1986\u20132015. J Huntingt Dis 7(1):77\u201386.","DOI":"10.3233\/JHD-170270"},{"issue":"9","key":"4147_CR16","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","volume":"83","author":"RS Finkel","year":"2014","unstructured":"Finkel RS, McDermott MP, Kaufmann P, Darras BT, Chung WK, Sproule DM, et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology. 2014;83(9):810\u20137.","journal-title":"Neurology"},{"issue":"20","key":"4147_CR17","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1212\/01.wnl.0000290830.40544.b9","volume":"69","author":"M Oskoui","year":"2007","unstructured":"Oskoui M, Levy G, Garland CJ, Gray JM, O\u2019Hagen J, De Vivo DC, et al. The changing natural history of spinal muscular atrophy type 1. Neurology. 2007;69(20):1931\u20136.","journal-title":"Neurology"},{"issue":"1","key":"4147_CR18","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/ejh.13410","volume":"105","author":"D Farmakis","year":"2020","unstructured":"Farmakis D, Giakoumis A, Angastiniotis M, Eleftheriou A. The changing epidemiology of the ageing thalassaemia populations: A position statement of the thalassaemia international federation. Eur J Haematol. 2020;105(1):16\u201323.","journal-title":"Eur J Haematol"},{"issue":"8","key":"4147_CR19","doi-asserted-by":"publisher","first-page":"e696","DOI":"10.1212\/WNL.0000000000006050","volume":"91","author":"M Pane","year":"2018","unstructured":"Pane M, Palermo C, Messina S, Sansone VA, Bruno C, Catteruccia M, et al. An observational study of functional abilities in infants, children, and adults with type 1 SMA. Neurology. 2018;91(8):e696\u2013703.","journal-title":"Neurology"},{"issue":"5","key":"4147_CR20","doi-asserted-by":"publisher","first-page":"889","DOI":"10.3233\/JND-230248","volume":"11","author":"Y Mart\u00ed","year":"2024","unstructured":"Mart\u00ed Y, Aponte Ribero V, Batson S, Mitchell S, Gorni K, Gusset N, et al. A systematic literature review of the natural history of Respiratory, Swallowing, Feeding, and speech functions in spinal muscular atrophy (SMA). J Neuromuscul Dis. 2024;11(5):889\u2013904.","journal-title":"J Neuromuscul Dis"},{"key":"4147_CR21","doi-asserted-by":"crossref","unstructured":"Chen KA, Widger J, Teng A, Fitzgerald DA, D\u2019Silva A, Farrar M. Real-world respiratory and bulbar comorbidities of SMA type 1 children treated with nusinersen: 2-Year single centre Australian experience. Paediatr Respir Rev. 2021 Sept;39:54\u201360.","DOI":"10.1016\/j.prrv.2020.09.002"},{"key":"4147_CR22","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ejpn.2024.08.006","volume":"53","author":"EF Tizzano","year":"2024","unstructured":"Tizzano EF, Quijano-Roy S, Servais L, Parsons JA, Aharoni S, Lakhotia A, et al. Outcomes for patients in the RESTORE registry with spinal muscular atrophy and four or more SMN2 gene copies treated with onasemnogene abeparvovec. Eur J Paediatr Neurol EJPN Off J Eur Paediatr Neurol Soc. 2024;53:18\u201324.","journal-title":"Eur J Paediatr Neurol EJPN Off J Eur Paediatr Neurol Soc"},{"issue":"23","key":"4147_CR23","doi-asserted-by":"publisher","first-page":"8989","DOI":"10.3390\/ijerph17238989","volume":"17","author":"I Aranda-Reneo","year":"2020","unstructured":"Aranda-Reneo I, Pe\u00f1a-Longobardo LM, Oliva-Moreno J, Litzkendorf S, Durand-Zaleski I, Tizzano EF, et al. The burden of spinal muscular atrophy on informal caregivers. Int J Environ Res Public Health. 2020;17(23):8989.","journal-title":"Int J Environ Res Public Health"},{"issue":"5","key":"4147_CR24","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1007\/s00415-022-11551-8","volume":"270","author":"PJC van Lonkhuizen","year":"2023","unstructured":"van Lonkhuizen PJC, Frank W, Heemskerk AW, van Duijn E, de Bot ST, M\u00fchlb\u00e4ck A, et al. Quality of life, health-related quality of life, and associated factors in huntington\u2019s disease: a systematic review. J Neurol. 2023;270(5):2416\u201337.","journal-title":"J Neurol"},{"key":"4147_CR25","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12955-016-0575-7","volume":"15","author":"MR van Walsem","year":"2017","unstructured":"van Walsem MR, Howe EI, Ruud GA, Frich JC, Andelic N. Health-related quality of life and unmet healthcare needs in huntington\u2019s disease. Health Qual Life Outcomes. 2017;15:6.","journal-title":"Health Qual Life Outcomes"},{"issue":"3","key":"4147_CR26","doi-asserted-by":"publisher","first-page":"125","DOI":"10.12968\/ijpn.2007.13.3.23274","volume":"13","author":"E Travers","year":"2007","unstructured":"Travers E, Jones K, Nichol J. Palliative care provision in huntington\u2019s disease. Int J Palliat Nurs. 2007;13(3):125\u201330.","journal-title":"Int J Palliat Nurs"},{"key":"4147_CR27","unstructured":"Paulson HL, Albin RL. Huntington\u2019s Disease: Clinical Features and Routes to Therapy. In: Lo DC, Hughes RE, editors. Neurobiology of Huntington\u2019s Disease: Applications to Drug Discovery [Internet]. Boca Raton (FL): CRC Press\/Taylor & Francis; 2011 [cited 2025 Sept 24]. (Frontiers in Neuroscience). Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK56000\/"},{"issue":"2","key":"4147_CR28","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1007\/s00415-022-11418-y","volume":"270","author":"H Furby","year":"2023","unstructured":"Furby H, Moore S, Nordstroem AL, Houghton R, Lambrelli D, Graham S, et al. Comorbidities and clinical outcomes in adult- and juvenile-onset huntington\u2019s disease: a study of linked Swedish National registries (2002\u20132019). J Neurol. 2023;270(2):864\u201376.","journal-title":"J Neurol"},{"key":"4147_CR29","doi-asserted-by":"publisher","unstructured":"Moskowitz AACB. Huntington\u2019s disease. Part 3: family aspects of HD. Br J Nurs [Internet]. 2013 Sept 27 [cited 2025 Sept 24]; Available from: https:\/\/www.magonlinelibrary.com\/doi\/https:\/\/doi.org\/10.12968\/bjon.2008.17.5.28830.","DOI":"10.12968\/bjon.2008.17.5.28830"},{"issue":"2","key":"4147_CR30","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s41669-024-00550-2","volume":"9","author":"C Udeze","year":"2025","unstructured":"Udeze C, Li N, Kunzweiler C, Baldwin J, Tuzin P, Zingel SD, et al. Clinical complications and healthcare resource utilization associated with conventional management of sickle cell disease with recurrent Vaso-occlusive crises and Transfusion-Dependent \u03b2-Thalassemia in Germany. PharmacoEconomics - Open. 2025;9(2):291\u2013300.","journal-title":"PharmacoEconomics - Open"},{"key":"4147_CR31","doi-asserted-by":"crossref","unstructured":"Drahos J, Boateng-Kuffour A, Calvert M, Levine L, Dongha N, Li N et al. Health-related quality of life and economic impacts in adults with transfusion-dependent \u03b2-thalassemia: findings from a prospective longitudinal real-world study. Qual Life Res. 2025 July 1;34(7):2005\u201317.","DOI":"10.1007\/s11136-025-03961-8"},{"key":"4147_CR32","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.2147\/DDDT.S214174","volume":"16","author":"HT Hjartarson","year":"2022","unstructured":"Hjartarson HT, Nathorst-B\u00f6\u00f6s K, Sejersen T. Disease modifying therapies for the management of children with spinal muscular atrophy (5q SMA): an update on the emerging evidence. Drug Des Devel Ther. 2022;16:1865\u201383.","journal-title":"Drug Des Devel Ther"},{"key":"4147_CR33","doi-asserted-by":"publisher","first-page":"104441596","DOI":"10.1016\/j.nmd.2024.07.605","volume":"43","author":"L Servais","year":"2024","unstructured":"Servais L, Alecu I, Lopez-Leon S, Ilic A, Brueckner A, Benguerba K, et al. 161P Long-term safety of onasemnogene abeparvovec for patients with spinal muscular atrophy: real-world findings from the RESTORE registry. Neuromuscul Disord. 2024;43:104441596.","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"4147_CR34","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3233\/JND-230122","volume":"11","author":"L Servais","year":"2024","unstructured":"Servais L, Day JW, De Vivo DC, Kirschner J, Mercuri E, Muntoni F, et al. Real-World outcomes in patients with spinal muscular atrophy treated with onasemnogene abeparvovec monotherapy: findings from the RESTORE registry. J Neuromuscul Dis. 2024;11(2):425\u201342.","journal-title":"J Neuromuscul Dis"},{"issue":"6","key":"4147_CR35","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s10198-024-01754-3","volume":"26","author":"S van der Schans","year":"2025","unstructured":"van der Schans S, Velikanova R, Weidlich D, Howells R, Patel A, Bischof M, et al. Cost comparison analysis of onasemnogene abeparvovec and Nusinersen for treatment of patients with spinal muscular atrophy type 1 in the Netherlands. Eur J Health Econ. 2025;26(6):1101\u201310.","journal-title":"Eur J Health Econ"},{"key":"4147_CR36","doi-asserted-by":"crossref","unstructured":"Latzer IT, Sagi L, Lavi R, Aharoni S, Bistritzer J, Noyman I et al. Real-Life outcome after gene replacement therapy for spinal muscular atrophy: A multicenter Experience. Pediatr neurol. 2023 July 1;144:60\u20138.","DOI":"10.1016\/j.pediatrneurol.2023.04.007"},{"issue":"15supplement","key":"4147_CR37","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1212\/WNL.94.15_supplement.1808","volume":"94","author":"JR Mendell","year":"2020","unstructured":"Mendell JR, Shell R, Lehman KJ, McColly M, Lowes LP, Alfano LN, et al. Gene-Replacement therapy in spinal muscular atrophy type 1: Long-Term Follow-Up from the onasemnogene Abeparvovec-xioi phase 1\/2a clinical trial (1808). Neurology. 2020;94(15supplement):1808.","journal-title":"Neurology"},{"issue":"5","key":"4147_CR38","doi-asserted-by":"publisher","first-page":"e479","DOI":"10.1097\/HS9.0000000000000479","volume":"4","author":"JB Kunz","year":"2020","unstructured":"Kunz JB, Kulozik AE. Gene therapy of the hemoglobinopathies. HemaSphere. 2020;4(5):e479.","journal-title":"HemaSphere"},{"issue":"1","key":"4147_CR39","doi-asserted-by":"publisher","first-page":"15","DOI":"10.14802\/jmd.21006","volume":"15","author":"S Byun","year":"2022","unstructured":"Byun S, Lee M, Kim M. Gene therapy for huntington\u2019s disease: the final strategy for a cure? J Mov Disord. 2022;15(1):15\u201320.","journal-title":"J Mov Disord"},{"key":"4147_CR40","doi-asserted-by":"crossref","unstructured":"Jacob J, Norris R, Oberm\u00fcller D, Alibone M, Ludwig M, ISPOR | International Society For Pharmacoeconomics and Outcomes Research. [cited 2025 Apr 14]. Data Standardization of Claims Data in the InGef Research Database: a Comparison of Data Models for Epidemiological and Economic Studies of Rare Genetic Diseases in Germany. Available from: https:\/\/www.ispor.org\/heor-resources\/presentations-database\/presentation\/euro2024-4014\/143357","DOI":"10.1016\/j.jval.2024.10.3613"},{"key":"4147_CR41","doi-asserted-by":"publisher","unstructured":"Kratzer VRV, Bidlingmaier C, Klamroth R, Behringer J, Schramm A, Mansmann U, Berger K. Can German Health Insurance Claims Data Fill Information Gaps in Rare Chronic Diseases: Use Case of Haemophilia A. H\u00e4mostaseologie [Internet]. 2024 July 1;(EFirst). Available from: http:\/\/www.thieme-connect.com\/products\/ejournals\/abstract\/https:\/\/doi.org\/10.1055\/a-2276-4871","DOI":"10.1055\/a-2276-4871"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04147-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-04147-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04147-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T14:02:11Z","timestamp":1781618531000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-025-04147-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4147"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-04147-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6564544\/v1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"30 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The anonymization of the InGef research database ensures that individual patients, health insurance companies and service providers can no longer be identified. In accordance with German law, separate approval of an institutional review board or Medical Ethics Committee was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"617"}}